• Proceedings of the PSK Conference
• /
• 2001.10a
• /
• pp.252.2-253
• /
• 2001

• Proceedings of the PSK Conference
• /
• 2001.10a
• /
• pp.277.2-277.2
• /
• 2001

• Proceedings of the Ginseng society Conference
• /
• 1993.09a
• /
• pp.187-194
• /
• 1993

• Advances in Traditional Medicine
• /
• v.4 no.3
• /
• pp.197-209
• /
• 2004

The study was aimed at evaluating the antioxidant and antimicrobial activities of methanol extract of Caesalpinia bonducella leaves (MECB) (Family: Caesalpiniaceae). The effect of MECB on antioxidant activity, reducing power, free radical scavenging (DPPH radical, nitric oxide radical, superoxide anion radical, hydroxyl radical and hydrogen peroxide radical scavenging), total phenolic content and antimicrobial activities were studied. The antioxidant activity of MECB increased in a dose dependent manner. About 50, 100, 250 and 500 g of MECB showed 53.4, 61.2, 69.1 and 76.2 % inhibition respectively on peroxidation of linoleic acid emulsion. Like antioxidant activity, the effect of MECB on reducing power increased in a dose dependent manner. The free radical scavenging activity of MECB was determined by DPPH radical scavenging method. The potency of this activity was increased with increased amount of extract. MECB was found to inhibit the nitric oxide radicals generated from sodium nitroprusside $(IC_{50}\;=\;102.8\;g/ml)$ whereas the $IC_{50}$ value of curcumin was 20.4 g/ml. Moreover, the MECB was found to scavenge the superoxide generated by photoreduction of Riboflavin. MECB was also found to inhibit the hydroxyl radical generated by Fenton reaction, where the $IC_{50}$ value is 104.17 g/ml compared with catechin 5 g/ml, which indicates the antioxidant activity of MECB. The MECB capable of scavenging hydrogen peroxide in a concentration-dependent manner. The amounts of total phenolic compounds were also determined. Antimicrobial activities of MECB were carried out using disc diffusion methods with five Gram positive, four Gram negative and four fungal species. The results obtained in the present study indicate that MECB leaves are potential source of natural antioxidant and antimicrobial agents.

• Advances in Traditional Medicine
• /
• v.7 no.3
• /
• pp.244-253
• /
• 2007

The present study was carried out to investigate the antihyperglycemic, antihyperlipidemic and antioxidant effect of chloroform and methanol extract of whole plant of Ichnocarpus frutescens (CEIF and MEIF) in streptozotocin (STZ)-induced diabetic rats. Administration of CEIF and MEIF orally at the dose of 200 mg/kg and 400 mg/kg body weight resulted in significant (P<0.01) reduction in blood glucose levels. The body weights were significantly (P<0.001) reduced in STZ-induced diabetic rats when compared to normal rats while the extracts significantly (P<0.01) prevented the decrease in body weight in the CEIF and MEIF treated rats. The study was further undertaken to evaluate the antioxidant and antihyperlipidemic potential of CEIF and MEIF in STZ-induced diabetic rats. The increased levels of lipid peroxidation in the liver tissues of diabetic rats were significantly reverted back to normal levels and a significant increase in activity of antioxidant enzymes such as superoxide dismutase, catalase and the level of reduced glutathione in the liver of diabetic rats after the treatment with CEIF and MEIF was noticed. These results clearly indicate that CEIF and MEIF exhibit significant antihyperglycemic, antihyperlipidemic and in vivo antioxidant activity in STZ-induced diabetic rats and the results were found to be in a dose dependent manner.

• Korean Journal of Clinical Pharmacy
• /
• v.31 no.3
• /
• pp.171-179
• /
• 2021

Background: Need for regulatory science is emerging with the development of pharmaceutical industry. It is essential to train regulatory science experts to meet the needs of technology and regulations to evaluate advanced products. Major regulatory science countries are conducting the regulatory science activities and fostering the experts. Methods: Published literature and the relevant website of European Union (EU) were reviewed and criteria were developed. In particular, we focused on in depth descriptions of the Innovative Medicines Initiative program, which was conducted twice. Results: EU is striving to provide funding and training experts for the development of the regulatory science by horizon 2020 and regulatory science to 2025. Innovative medicines initiative (IMI) is a public-private partnership aimed at the development of the pharmaceutical industry, including the regulatory science. IMI education and training projects have provided various education and training course including short-term curriculum and master and doctoral course. The difference between South Korea's regulatory science expert training project in 2021 and the EU's IMI education and training projects is participation of pharmaceutical companies. While the pharmaceutical companies participate in the IMI project to select project topics and form a community, South Korea's project is focused on the Ministry of Food and Drug Safety and universities. Conclusion: Through successful active networks with regulatory party, pharmaceutical companies, and universities, a great innovative advance of regulatory science in South Korea is expected.

• Molecules and Cells
• /
• v.27 no.1
• /
• pp.127-127
• /
• 2009

• Proceedings of the PSK Conference
• /
• 2002.10a
• /
• pp.249.2-250
• /
• 2002

Tolerance and pharmacolinetics after single-dose administration of DA-8159, a new selective PDE5 inhibitor under phase 1 study, were examined in 42 healthy male volunteers in a six-period, double-blinded placebo-controlled study. Participants received single oral tablet of DA-8159 (12.5 to 300mg) or placebo. Adverse effects and pharmacokinetic parameters were monitored during experiments. DA-8159 was well tolerated and the frequency of adverse events was dose-related. (omitted)

• The Korean Society of Law and Medicine
• /
• v.12 no.2
• /
• pp.65-117
• /
• 2011

This article analyzes the case (2008Da16776) which has the issue how patients have to prove causal relationship when patients claim against pharmaceutical companies alleging that patients were infected with virus due to contaminated blood products. The Supreme court held that: (1) if patients prove that they didn't have symptoms suggesting virus infection before administration of blood products, the virus infection had been confirmed after administration of blood products, and there were significant potential of contamination of the blood products with the virus, the defect in blood products or the negligence of pharmaceutical company in making blood products shall be presumed to cause the infection of the victim. (2) The pharmaceutical companies could reverse the presumption by proving the blood products were not contaminated, but the fact that the victims were treated with the blood products manufactured by other companies or had received blood transfusions is not enough to reverse the presumption. The case is the first decision whether the burden of proof about causal relationship could be reduced in pharmaceutical product liability lawsuit. Hereafter pharmaceutical product liability cases, it would be necessary to reduce the burden of proof about causal relationship in order to make substantive equality between patients and pharmaceutical companies.

• YAKHAK HOEJI
• /
• v.41 no.5
• /
• pp.559-564
• /
• 1997

To find out antitumor active principles from natural resources, we have evaluated various extracts from the leaves of Alnus hirsuta (Betulaceae). The ethylacetate extract of this plant was found to show a significant cytotoxicity against several kinds of cultured human solid tumor cell lines (AGS, A5 49, HCT15, SKOV3, HEP3B) in vitro. Using cytotoxicity-guided chromatographic purification of the ethylacetate extract, cytotoxic constituent:1,7-bis-(4-hydroxyphenyl)-5-(${\beta}$-D-glucopyranosyloxy)-3-heptanone, was isolated and structurally identified by physico-chemical properties and spectroscopic evidences.